Coherus BioSciences

Coherus BioSciences Product

• Cimerli®

  • Generic: ranibizumab‑eqrn

  • Indication: biosimilar to Lucentis® for age-related macular degeneration and related eye conditions

L

• Loqtorzi®

  • Generic: toripalimab‑tpzi

  • Indication: anti‑PD‑1 immunotherapy approved for recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination with chemotherapy or as monotherapy

U

• Udenyca® (previously marketed; divested 2024)

  • Generic: pegfilgrastim‑cbqv

  • Indication: biosimilar to Neulasta®, used to reduce the incidence of infection (febrile neutropenia) in patients undergoing myelosuppressive anti-cancer treatment

Y

• Yusimry®

• Generic: adalimumab‑aqvh

• Indication: biosimilar to Humira® for various autoimmune inflammatory diseases (e.g., rheumatoid arthritis, psoriasis)